Analysts' Actions -- Cabot, International Paper, Range Resources and More

RATINGS CHANGES

Cabot Oil & Gas (COG) was upgraded to overweight from neutral at JPMorgan. $27 price target. Atlantic Sunrise should drive growth, JPMorgan said. 

Fortinet (FTNT) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: FTNT.

International Paper (IP) was downgraded to underweight from equal-weight at Barclays. $45 price target. The company is highly leveraged and consensus expectations appear too high, Barclays said.

Piper Jaffray (PJC) was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: PJC.

PRA Health (PRAH) was upgraded to outperform from neutral at Credit Suisse. $67 price target. Earnings estimates were also upped, given the recent Takeda partnership, Credit Suisse said. 

Parexel (PRXL) was downgraded to neutral from outperform at Credit Suisse. $65 price target. The company lacks near-term visibility, Credit Suisse said. 

Range Resources (RRC) was upgraded to buy from neutral at Nomura. $45 price target. The stock has lagged, but the company's fundamentals are improving, Nomura said. 

Validus (VR) was downgraded to hold at Deutsche Bank. $56 price target. The valuation is less attractive as the stock is up 20% over the past six months. 

Vista Outdoor (VSTO) was downgraded to neutral from buy at DA Davidson. $28 price target. Growth headwinds are increasing, Davidson said. 

This article was written by a staff member of TheStreet.

More from Stocks

Banks Prepare to Up Shareholder Payouts By $30 Billion

Banks Prepare to Up Shareholder Payouts By $30 Billion

Starbucks Just Revealed Some of the Most Worrying Data in Its History

Starbucks Just Revealed Some of the Most Worrying Data in Its History

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Biotech Firm Sarepta Surges 40% on Positive Test Results

Biotech Firm Sarepta Surges 40% on Positive Test Results